The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function

American Journal of Pathology

Volumn 162, Issue 1, 2003, Pages 233-241

  Comuzzi, Barbara ^a   Lambrinidis, Leonidas ^a,e   Rogatsch, Hermann ^b   Godoy Tundidor, Sonia ^a   Knezevic, Nikola ^d   Krhen, Ivan ^d   Marekovic, Zvonimir ^d   Bartsch, Georg ^a   Klocker, Helmut ^a   Hobisch, Alfred ^a,c   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c General Hospital Feldkirch   (Austria)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HYDROXYFLUTAMIDE;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; EPITHELIUM CELL; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0037222317     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63814-X     Document Type: Article

References (54)

1. Huggins C, Hodges CV: Studies on prostatic cancer: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297
2. Labrie F, Dupont A, Belanger A, Lefebvre FA. Cusan L, Raynaud JP, Husson JM, Fazekas AT: New hormonal therapy in prostate cancer: Combined use of a pure antiandrogen and an LHRH agonist. Horm Res 1983, 18:18-27
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IMJ, Bueschen AJ, Lowe BA: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042
4. Blackledge GR: High-dose bicalutamide monotherapy for the treatment of prostate cancer Urology 1996, 47:44-47
5. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H: Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993, 7:1541-1550
6. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406
7. Kokontis J, Takakura K, Hay N, Liao S: Increased androgen receptor, activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994, 54:1566-1573
8. Gregory CW, Johnson RTJ, Mohler JL, French FS, Wilson EM: Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001, 61:2892-2898
9. Culig Z, Klocker H, Bartsch G, Hobisch A: Mutations of androgen receptor in carcinoma of the prostate - Significance for endocrine therapy. Am J Pharmacogenomics 2001, 1:241-249
10. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59:2511-2515
11. Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998, 95:7379-7384
12. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61:4315-4319
13. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CE: Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001, 85:1928-1936
14. Fronsdal K, Engedal N, Hagsvold T, Saatcioglu F: CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 1998, 273:31853-31859
15. Aarnisalo P, Palvimo JJ, Janne OA: CREB binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 1998, 95:2122-2127
16. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG: p300 and p300/cAMP- response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 2000, 275:20853-20860
17. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG: Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 2001, 15:797-811
18. Chan HM, La Thangue NB: p300/CBP proteins: hATs for transcriptional bridges and scaffolds. J Cell Sci 2001, 114:2363-2373
19. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP: Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 1995, 92:5451-5455
20. Muraoka M, Konishi M, Kikuchi R, Tanaka K, Shitara N, Chong JM, Iwama T, Miyaki M: p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996, 12:1565-1569
21. Xu L, Glass CK, Rosenfeld MG: Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet 1999, 9:140-147
22. Liu YZ, Chirivia JC, Latchman DS: Nerve growth factor up-regulates the transcriptional activity of CBP through activation of the p42/p44 (MAPK) cascade. J Biol Chem 1998, 273:32400-32407
23. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998, 58:4640-4645
24. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C: From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999, 96:5458-5463
25. Culig Z, Hoffmann J, Erdel M, Eder I, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H: Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999, 81:242-251
26. Gleason DF: Histologic grading of prostate cancer: A perspective Hum Pathol 1992, 23:273-279
27. Bankfalvi A, Navabi H, Bier B, Böoker W, Jasani B, Schmid KW: Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol 1994, 174:223-228
28. Kemppainen JA, Wilson EM: Agonist and antagonist activities of hydroxyflutamide and casodex relate to androgen receptor stabilization. Urology 1996, 48:157-163
29. Avances C, Georget V, Terouanne B, Orio F, Cussenot O, Mottet N, Costa P, Sultan C: Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens. Mol Cell Endocrinol 2001, 184:13-24
30. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992, 89:6319-6323
31. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato AC: Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 1995, 63:544-550
32. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43:1809-1818
33. Kaighn ME, Shankar Narayan K, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17:16-23
34. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978, 21:274-281
35. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997, 3:1383-1388
36. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVereWhite RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997, 11: 450-459
37. Wong CI, Kelce WR, Sar M, Wilson EM: Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 1995, 270:19998-20003
38. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990, 17:534-540
39. Zhao XY, Boyle B, Krishman AV, Navone NM, Peehl DM, Feldman D: Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 1999, 162:2192-2199
40. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 332:1393-1398
41. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ: Androgen receptor mutations in prostate cancer. Cancer Res 2000, 60:944-949
42. Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ, Young CY: Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology 1999, 140:1665-1671
43. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, Culig Z: Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 2000, 82:39-45
44. Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999, 5:280-285
45. Truica CI, Byers S, Gelmann EP: Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000, 60:4709-4713
46. Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A: Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 2001, 46:319-326
47. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993, 11:1566-1572
48. Laufer M, Sinibaldi VJ, Carducci MA, Eisenberger MA: Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology 1999, 54:745
49. Nieh PT: Withdrawal phenomenon with the antiandrogen casodex. J Urol 1995, 153:1070-1072
50. Small PJ, Carroll PR: Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 1994, 44:790-792
51. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ, Koivisto PA: Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001, 81:1647-1651
52. Nessler-Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G, Klocker H: Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 2000, 45:124-131
53. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schule R: FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 2000, 19:359-369
54. Debes JD, Schmidt LJ, Huang H, Tindall DJ: p300 mediates interleukin-6-dependent transactivation of the androgen receptor. Proc AACR 2002, 43:161 (Abstract)